Ono Pharmaceutical will pay $25.60 per share in an all-cash deal to buy Deciphera Pharmaceuticals for its potential ...

Bristol Myers Squibb’s deal announced Monday will see the pharma pay $65 million upfront to Repertoire Immune Medicines, ...

Citing anonymous sources involved in a Phase III trial, STAT News reported Sunday that MorphoSys’ pelabresib may worsen the ...

A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose ...

After a record low in 2022, the pharma industry in 2023 saw a surprise rebound in productivity following one of its slowest ...

Johnson & Johnson and Addex Therapeutics’ epilepsy hopeful ADX71149 did not meet its primary endpoint of time to reach ...

After laying off staff in 2022 to extend its cash runway, X4 Pharmaceuticals got its drug for the ultra-rare immunodeficiency ...

With GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore ...

As the Phase III amyotrophic lateral sclerosis pipeline thins out, the ALS community is placing its hopes on earlier-stage ...

Phase II data indicate Larimar Therapeutics’ injectable therapy nomlabofusp could go head-to-head in the market with Biogen's ...

Takeda Oncology US Head of Sales, Annette Montandon, discusses how embodying a patient-first approach is key to the success ...

Is there a connection between Bristol Myers Squibb’s announcement that it will reduce its headcount by 6% and the company’s ...